Novartis Certican Short-Term Renal Safety Study Suggested By Panel

A short-term renal toxicity study establishing the safety of Novartis' Certican with lower doses of cyclosporine could sway members of FDA's Cardiovascular & Renal Drugs Advisory Committee to recommend approval of the immunosuppressant in heart transplantation